TCTR20211226001CompletedPhase 3
Circulating Tumor Cells (CTCs) A prognostic biomarker in Patients with Hepatocellular Carcinoma
/A0 sites73 target enrollmentStarted: December 26, 2021Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Enrollment
- 73
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 Years to N/A (No limit) (—)
- Sex
- All
Inclusion Criteria
- •The inclusion criteria were newly diagnosed HCC patients with age more than 18 years. The diagnosis of HCC was defined according to American Association of the Study of Liver Diseases guidelines.
Exclusion Criteria
- •The exclusion criteria were patients with previous or concurrent other malignancies.
Investigators
Similar Trials
Completed
Not Applicable
The Value of Diagnosis and Outcome Prediction in CTC for Metastatic NPC PatientsNasopharyngeal NeoplasmsNCT02505139Sun Yat-sen University166
Completed
Not Applicable
Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal CancerClear Cell Renal CancerCirculating Tumor CellsCirculating Endothelial CellsPrognostic BiomarkersPredictive BiomarkersNCT02499458Lawson Health Research Institute44
Completed
Not Applicable
Circulating Tumour Cells as Biomarkers to Predict Prostate Cancer Metastasis for Treatment Stratification of CancerProstate CancerNCT05533515Queen Mary University of London330
Terminated
Not Applicable
Prognostic Value of CTC in HNSCC PatientsRecurrenceMetastasisDeathNCT01884129Chang Gung Memorial Hospital53
Recruiting
Not Applicable
Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer PatientsBreast NeoplasmsNeoplastic Cells, CirculatingChemotherapy EffectNCT05326295Hunan Cancer Hospital1,000